Deferiprone 400mg/5ml oral suspension
Requires a prescription from a doctor or prescriber
Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Deferiprone
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Deferiprone
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 12 · Randomised trials: 20 · 1995–2026
Showing the 50 most relevant studies, sorted by most relevant.
Antonio Martín‐Bastida, Roberta J. Ward, Rexford D. Newbould, et al.
Scientific Reports, 2017
- Deferiprone
- Brain
- Brain Chemistry
Dudley J. Pennell
Blood, 2005
- Deferiprone
- Deferoxamine
- Iron
Mark Tanner, R. Galanello, C. Dessì, et al.
Circulation, 2007
- Deferiprone
- Agranulocytosis
- Deferoxamine
Aurelio Maggio, Gennaro D’Amico, Alberto Morabito, et al.
Blood Cells Molecules and Diseases, 2002
- Deferiprone
- Deferoxamine
- Ferritins
Thomas Klopstock, Fernando Tricta, Lynne Neumayr, et al.
The Lancet Neurology, 2019
- Deferiprone
- Pantothenate Kinase-Associated Neurodegeneration
Ahmed Negida, N.M.S. Hassan, H. Aboeldahab, et al.
CNS Neuroscience & Therapeutics, 2024
Ahmed Salem, Payal Desai, Ahmed Elgebaly
Cureus, 2023
Alla D, Shah D, Ramsundar R, et al.
2026
- Parkinson Disease
- Antiparkinson Agents
- Iron Chelating Agents
Wilar G, Suhandi C, Kawahata I
2025
- Thalassemia
- Iron Chelating Agents
- Deferiprone
George J. Kontoghiorghes, Christina Kontoghiorghe
Drug Design Development and Therapy, 2016
- Deferiprone
- Deferasirox
- Benzoates
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
1.9 hours
Mechanism
Deferiprone is an iron chelator that binds to ferric ions (iron III) and forms a…
Food interactions
1 warning
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
1 hour
Half-life
1.9 hours
Protein binding
10%
Volume of distribution
1L/kg
Metabolism
Elimination
5-6 hours
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 809 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC V03AC02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Deferiprone
Additional database identifiers
Drugs Product Database (DPD)
22561
ChemSpider
2866
BindingDB
50525976
ZINC
ZINC000000006226
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12538
GeneCards
UGT1A6
UniProt Accession
UD16_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q749664), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.